Amidst the growing market concerns U.S. Congress delays bill, targeting Chinese biotech companies
The legislation aims at restricting federal agencies from entering into contracts with several prominent Chinese biotech companies, including BGI Group, MGI, Complete Genomics, and WuXi AppTec, along with their subsidiaries.